Abstract

Viridans group streptococci (VGS), especially the Streptococcus mitis-oralis subgroup, are pivotal pathogens in a variety of invasive endovascular infections, including “toxic shock” in neutropenic cancer patients and infective endocarditis (IE). Previously, we showed that the serial in vitro passage of S. mitis-oralis strains in sublethal daptomycin (DAP) resulted in rapid, high-level and stable DAP-resistance (DAP-R), which is accompanied by distinct changes in several genotypic and phenotypic signatures: (1) the disappearance of two key membrane phospholipids, phosphatidylglycerol (PG) and cardiolipin (CL); (2) increased membrane fluidity; (3) increased positive surface charge; (4) single nucleotide polymorphisms (SNPs) in two loci involved in CL biosynthesis (pgsA; cdsA); and (5) DAP hyperaccumulation. The current study examined these same metrics following in vitro serial DAP passages of a separate well-characterized S. mitis-oralis bloodstream isolate (SF100). Although some metrics seen in prior DAP post-passage strains were recapitulated with SF100 (e.g., pgsA SNPs, enhanced membrane fluidity), we observed the following major differences (comparing the parental versus post-passage variant): (1) no change in PG content; (2) reduced, but not absent, CL, with enhancement in phosphatidic acid (PA) content; (3) an unusual pattern of CL localization; (4) significantly decreased positive surface charge; (5) no difference in DAP accumulation; and (6) no cdsA SNPs. Thus, S. mitis-oralis strains are not “pre-programmed” phenotypically and/or genotypically to adapt in an identical manner during the evolution of the DAP-R.

Highlights

  • Invasive infections caused by the S. mitis-oralis subgroup of viridans group streptococci (VGS), especially endovascular syndromes, are increasing in both nosocomial and community settings [1,2,3,4].For example, S. mitis-oralis is the second leading cause of infective endocarditis (IE) in the developing world [1,2,3,4]

  • The DAP-S parental SF100 S. mitis-oralis strain used in this study was identified by MALDI-TOF, and has a DAP MIC of 1 μg/mL [20])

  • This phenotype was stable on the passage of this DAP-R variant in antibiotic-free media

Read more

Summary

Introduction

S. mitis-oralis is the second leading cause of infective endocarditis (IE) in the developing world [1,2,3,4]. This subgroup is the most common cause of the “toxic Strep syndrome”. S. mitis-oralis strains have a propensity toward vancomycin-tolerance, further limiting therapeutic options. These antibiotic resistance scenarios have rendered daptomycin (DAP) as a plausible option for treating invasive infections with this emerging pathogen

Objectives
Methods
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call